Association between genetic polymorphisms in the promoter regions of let-7 and risk of papillary thyroid carcinoma: A case-control study

Medicine (United States)

Volumn 94, Issue 43, 2015, Pages

  Wang, Yichao ^a   Wei, Tao ^a   Xiong, Junjie ^a   Chen, Peng ^a   Wang, Xunli ^a   Zhang, Lin ^a   Gao, Linbo ^a   Zhu, Jingqiang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LET 7 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; MICRORNA; MIRNLET7 MICRORNA, HUMAN;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THYROID CARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID TUMOR;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; THYROID NEOPLASMS;

EID: 84946572154     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001879     Document Type: Article

References (33)

1. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
2. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol). 2010;22:395-404.
3. Liu S, Semenciw R, Ugnat AM, et al. Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. Br J Cancer. 2001;85:1335-1339.
4. Cummings AL, Goldfarb M. Thyroid carcinoma metastases to axillary lymph nodes: report of two rare cases of papillary and medullary thyroid carcinoma and literature review. Endocr Pract. 2014;20:e34-e37.
5. Sakorafas GH, Sampanis D, Safioleas M. Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties. Surg Oncol. 2010;19:e57-e70.
6. Wang P, Lv L, Qi F, et al. Increased risk of papillary thyroid cancer related to hormonal factors in women. Tumour Biol. 2015;36:5127-5132.
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
8. Tsuchiya S, Okuno Y, Tsujimoto G. MicroRNA: biogenetic and functional mechanisms and involvements in cell differentiation and cancer. J Pharmacol Sci. 2006;101:267-270.
9. Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010;70:9798-9807.
10. Jackson BL, Grabowska A, Ratan HL. MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers. BMC Cancer. 2014;14:930.
11. Lee JC, Gundara JS, Glover A, et al. MicroRNA expression profiles in the management of papillary thyroid cancer. Oncologist. 2014;19:1141-1147.
12. Pallante P, Visone R, Ferracin M, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 2006;13:497-508.
13. Ricarte-Filho JC, Fuziwara CS, Yamashita AS, et al. Effects of let-7 microRNA on cell growth and differentiation of papillary thyroid cancer. Transl Oncol. 2009;2:236-241.
14. Mudduluru G, Vajkoczy P, Allgayer H. Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Mol Cancer Res. 2010;8:159-169.
15. Kröger A, Köster M, Schroeder K, et al. Activities of IRF-1. J Interferon Cytokine Res. 2002;22:5-14.
16. Xie K, Liu J, Zhu L, et al. A potentially functional polymorphism in the promoter region of let-7 family is associated with survival of hepatocellular carcinoma. Cancer Epidemiol. 2013;37:998-1002.
17. Liang Y, Zhao G, Sun R, et al. Genetic variants in the promoters of let-7 family are associated with an increased risk of major depressive disorder. J Affect Disord. 2015;183:295-299.
18. Solé X, Guinó E, Valls J, et al. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22:1928-1929.
19. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120:635-647.
20. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull. 2006;29:903-906.
21. Kumar MS, Erkeland SJ, Pester RE, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A. 2008;105:3903-3908.
22. Li ZH, Pan XM, Han BW, et al. A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer. Tumour Biol. 2013;34:3159-3163.
23. Pan XM, Sun RF, Li ZH, et al. A let-7 KRAS rs712 polymorphism increases colorectal cancer risk. Tumour Biol. 2014;35:831-835.
24. Chin LJ, Ratner E, Leng S, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008;68:8535-8540.
25. Wang WY, Chien YC, Wong YK, et al. Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma. Head Neck. 2012;34:663-666.
26. Pan XM, Jia J, Guo XM, et al. Lack of association between let-7 binding site polymorphism rs712 and risk of nasopharyngeal carcinoma. Fam Cancer. 2014;13:93-97.
27. Jin H, Liang Y, Wang X, et al. Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer. Med Oncol. 2014;31:221.
28. Shen LQ, Xie YZ, Qian XF, et al. A single nucleotide polymorphism in the promoter region of let-7 family is associated with lung cancer risk in Chinese. Genet Mol Res. 2015;14:4505-4512.
29. Wang Z, Zhang H, Zhang P, et al. Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis. Med Oncol. 2013;30:577.
30. Duan R, Pak C, Jin P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet. 2007;16:1124-1131.
31. Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics. 2009;10:399-416.
32. Landi D, Moreno V, Guino E, et al. Polymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with colorectal cancer. Mutat Res. 2011;717:109-115.
33. Gao LB, Li LJ, Pan XM, et al. A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem. 2013;394:415-420.